

Appendix C
2004 Cardiovascular Biomarkers and Surrogate Endpoints Symposium
Agenda

Friday, September 10th

8:00am – 8:15am	Welcome and Conference Objectives Dr. Jean-Claude Tardif
8:15am – 8:30am	The Need for Biomarkers in Drug Development Dr. Therese Heinonen
8:30am – 8:50am	Pathophysiology of the Complicated Atherosclerotic Plaque Dr. Peter Libby
8:50am – 9:10am	Acute Coronary Syndromes Dr. Robert Harrington
9:10am – 9:30am	Biomarkers in Perspective Dr. Paul Ridker
9:30am – 9:50am	Question and Answer - Faculty
9:50am – 10:20am	<u>BREAK</u>
10:20am – 10:40am	A Tale of Two Trials Dr. Claude Lenfant
10:40am – 11:00am	Lipoproteins and Other Related Risk Factors Dr. Daniel Rader
11:00am – 11:20am	HDL Oxidation in the Pathogenesis of Atherosclerosis Dr. Jay Heinecke
11:20pm – 11:40am	The Role of Myeloperoxidase and NO-Derived Oxidants in Atherosclerosis Dr. Stanley Hazen
11:40am – 12:00pm	Question and Answer- Faculty
12:00pm – 1:00pm	<u>LUNCH</u>
1:00pm – 1:20pm	Markers of Risk and Response to Therapy in a Population with CAD and Low HDL-C Dr. B. Greg Brown
1:20pm – 1:40pm	Pharmacogenomics Dr. Michael Phillips
1:40pm – 2:00pm	Device Development Considerations Dr. Bram Zuckerman
2:00pm – 2:20pm	Special Considerations for the Diabetic Population Dr. George Steiner
2:20pm – 2:40pm	Markers of CV Disease: Application to Clinical Practice and Public Health Dr. George Mensah
2:40pm – 3:00pm	<u>BREAK</u>
3:00pm – 4:00pm	Question and Answer – Faculty/Panel Discussion – Dr. Peter Libby and Dr. Robert Harrington, Moderators
4:00pm	Conclusion – Day 1

Saturday, September 11th

8:00am – 8:10am	Summary and Introduction Dr. Peter Libby
8:10am – 8:30am	The Role of Imaging in CV Disease Detection and Treatment Dr. Jean-Claude Tardif
8:30am – 9:00am	Carotid IMT – A CAD surrogate? Dr. John Kastelein
9:00am – 9:30am	What’s “New” with IVUS? Dr. Steve Nissen
9:30am – 10:00am	Question and Answer - Faculty
10:00am – 10:30am	<u>BREAK</u>
10:30am – 10:50am	Endothelial Function and Current Evaluations Dr. Todd Anderson
10:50am – 11:10am	Practical Considerations in EBCT and Nuclear Imaging Dr. Paolo Raggi
11:10am – 11:30am	Magnetic Resonance Imaging of the High-Risk Atherosclerotic Plaque Dr. Thomas Hatsukami
11:30am – 11:50am	CT Angiography – On the Cutting Edge Dr. Pim de Feyter
11:50am – 12:30pm	Question and Answer – Faculty
12:30pm – 1:30pm	<u>LUNCH</u>
1:30pm – 1:50pm	How Does the FDA Cardio-Renal Department View Surrogate Endpoints? Dr. Douglas Throckmorton
1:50am – 2:10pm	How Does the FDA Metabolism and Endocrine Department View Surrogate Endpoints? Dr. David Orloff
2:10pm – 2:30pm	A Perspective from EMEA Dr. Eric Abadie
2:30pm – 2:50pm	A Perspective from Health Canada Dr. Guy Beaulieu
2:50pm – 3:20pm	The Pharma/Regulatory Interface Dr. Ray Lipicky
3:20pm – 3:40pm	<u>BREAK</u>
3:40pm – 4:30pm	Question and Answer – Faculty/ Panel Discussion - Dr. Jean-Claude Tardif and Dr. John Kastelein, Moderators
4:30pm	Closing Remarks Drs. Jean-Claude Tardif and Peter Libby